277 related articles for article (PubMed ID: 17931705)
41. Hemiparkinsonian rats rotate toward the side with the weaker dopaminergic neurotransmission.
Da Cunha C; Wietzikoski EC; Ferro MM; Martinez GR; Vital MA; Hipólide D; Tufik S; Canteras NS
Behav Brain Res; 2008 Jun; 189(2):364-72. PubMed ID: 18328580
[TBL] [Abstract][Full Text] [Related]
42. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats.
Reksidler AB; Lima MM; Zanata SM; Machado HB; da Cunha C; Andreatini R; Tufik S; Vital MA
Eur J Pharmacol; 2007 Apr; 560(2-3):163-75. PubMed ID: 17320073
[TBL] [Abstract][Full Text] [Related]
43. Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats.
Liu CQ; Chen Z; Liu FX; Hu DN; Luo JH
Neuropharmacology; 2007 Dec; 53(7):832-41. PubMed ID: 17919665
[TBL] [Abstract][Full Text] [Related]
44. Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra.
Dietz GP; Stockhausen KV; Dietz B; Falkenburger BH; Valbuena P; Opazo F; Lingor P; Meuer K; Weishaupt JH; Schulz JB; Bähr M
J Neurochem; 2008 Feb; 104(3):757-65. PubMed ID: 17995935
[TBL] [Abstract][Full Text] [Related]
45. Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra.
Jiang H; Li LJ; Wang J; Xie JX
Exp Neurol; 2008 Aug; 212(2):532-7. PubMed ID: 18577498
[TBL] [Abstract][Full Text] [Related]
46. Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease.
Zhang D; Anantharam V; Kanthasamy A; Kanthasamy AG
J Pharmacol Exp Ther; 2007 Sep; 322(3):913-22. PubMed ID: 17565007
[TBL] [Abstract][Full Text] [Related]
47. Influence of age and gender on cytokine expression in a murine model of Parkinson's disease.
Ciesielska A; Joniec I; Kurkowska-Jastrzebska I; Przybyłkowski A; Gromadzka G; Członkowska A; Członkowski A
Neuroimmunomodulation; 2007; 14(5):255-65. PubMed ID: 18196934
[TBL] [Abstract][Full Text] [Related]
48. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys.
Garrido-Gil P; Belzunegui S; San Sebastián W; Izal-Azcárate A; López B; Marcilla I; Luquin MR
J Neurosci Res; 2009 Feb; 87(2):586-97. PubMed ID: 18798285
[TBL] [Abstract][Full Text] [Related]
49. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
50. Cell survival patterns in the pedunculopontine tegmental nucleus of methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys and 6OHDA-lesioned rats: evidence for differences to idiopathic Parkinson disease patients?
Heise CE; Teo ZC; Wallace BA; Ashkan K; Benabid AL; Mitrofanis J
Anat Embryol (Berl); 2005 Nov; 210(4):287-302. PubMed ID: 16237536
[TBL] [Abstract][Full Text] [Related]
51. The influence of acute and chronic administration of 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline on the function of the nigrostriatal dopaminergic system in rats.
Lorenc-Koci E; Antkiewicz-Michaluk L; Kamińska A; Lenda T; Zieba B; Wierońska J; Smiałowska M; Schulze G; Rommelspacher H
Neuroscience; 2008 Oct; 156(4):973-86. PubMed ID: 18809471
[TBL] [Abstract][Full Text] [Related]
52. Fluoro-Jade C can specifically stain the degenerative neurons in the substantia nigra of the 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine-treated C57BL/6 mice.
Bian GL; Wei LC; Shi M; Wang YQ; Cao R; Chen LW
Brain Res; 2007 May; 1150():55-61. PubMed ID: 17397812
[TBL] [Abstract][Full Text] [Related]
53. Toki-to protects dopaminergic neurons in the substantia nigra from neurotoxicity of MPTP in mice.
Sakai R; Irie Y; Murata T; Ishige A; Anjiki N; Watanabe K
Phytother Res; 2007 Sep; 21(9):868-73. PubMed ID: 17486689
[TBL] [Abstract][Full Text] [Related]
54. Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.
Castro AA; Ghisoni K; Latini A; Quevedo J; Tasca CI; Prediger RD
Behav Brain Res; 2012 Apr; 229(1):208-15. PubMed ID: 22266923
[TBL] [Abstract][Full Text] [Related]
55. Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb.
Franco J; Prediger RD; Pandolfo P; Takahashi RN; Farina M; Dafre AL
Life Sci; 2007 Apr; 80(20):1906-14. PubMed ID: 17382353
[TBL] [Abstract][Full Text] [Related]
56. Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys.
Emborg ME; Shin P; Roitberg B; Sramek JG; Chu Y; Stebbins GT; Hamilton JS; Suzdak PD; Steiner JP; Kordower JH
Exp Neurol; 2001 Mar; 168(1):171-82. PubMed ID: 11170732
[TBL] [Abstract][Full Text] [Related]
57. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
[TBL] [Abstract][Full Text] [Related]
58. Acoustic startle response, prepulse inhibition, and spontaneous locomotor activity in MPTP-treated mice.
Leng A; Yee BK; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):449-56. PubMed ID: 15313033
[TBL] [Abstract][Full Text] [Related]
59. Protocol for the MPTP mouse model of Parkinson's disease.
Jackson-Lewis V; Przedborski S
Nat Protoc; 2007; 2(1):141-51. PubMed ID: 17401348
[TBL] [Abstract][Full Text] [Related]
60. Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice.
Nieto M; Gil-Bea FJ; Dalfó E; Cuadrado M; Cabodevilla F; Sánchez B; Catena S; Sesma T; Ribé E; Ferrer I; Ramírez MJ; Gómez-Isla T
Neurobiol Aging; 2006 Jun; 27(6):848-56. PubMed ID: 16006012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
